Literature DB >> 15324613

Current Management of Syncope: Treatment Alternatives.

Carlos A. Morillo1, Adrián Baranchuk.   

Abstract

Syncope, defined as a transient loss of consciousness and postural tone with spontaneous recovery and no neurologic sequelae, is among one of the most common causes of consultation with a physician. The diagnostic workup is complex but can be simplified if focused on the underlying condition. Prognosis is highly dependent on the presence or absence of structural heart disease, primarily the presence of cardiomyopathy regardless of etiology, particularly if the left ventricular (LV) function is less than 35%. The diagnostic approach to the patient with recurrent syncope and no structural heart disease is targeted to rule out neurally mediated causes. This approach usually includes a tilt table test (ie, head-up tilt), carotid sinus massage in patients older than 55 years, and an adenosine challenge test in patients who remain with unexplained syncope. Unexplained syncope in patients with reduced LV function (< 35%) may be potentially life-threatening. Infrequent causes of syncope should be sought in younger patients with a family history of sudden cardiac death. Channelopathies such as the long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia are among this variety. Therapy should address the potential mechanism of syncope. In neurally mediated causes, restoration of orthostatic tolerance, primarily by increasing volume during orthostatic stress, is recommended. Physiologic countermaneuvers and increase in salt and water intake are usually the initial therapy. With syncope in patients with an LV dysfunction (< 35%), an ICD is frequently recommended after ruling out common causes of syncope. Syncope in the elderly is usually multifactorial and therapy should include reassessment of multiple medications, which can promote neurally mediated syncope as well as searching for bradycardic causes. Empiric pacing may be used in this complex group of patients.

Entities:  

Year:  2004        PMID: 15324613     DOI: 10.1007/s11936-004-0021-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  57 in total

1.  Vasovagal susceptibility to nitrate or isoproterenol head-up tilt.

Authors:  J Niño; J C Villar; K U Tahvanainen; M Kähönen; T A Kuusela; C A Morillo
Journal:  Am J Cardiol       Date:  2001-12-01       Impact factor: 2.778

Review 2.  Drug induced QT prolongation and torsades de pointes.

Authors:  Yee Guan Yap; A John Camm
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

Review 3.  Current evaluation and management of syncope.

Authors:  Wishwa N Kapoor
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

4.  The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope.

Authors:  S J Connolly; R Sheldon; R S Roberts; M Gent
Journal:  J Am Coll Cardiol       Date:  1999-01       Impact factor: 24.094

5.  Successful treatment of severe orthostatic hypotension with erythropoietin.

Authors:  Kazunobu Kawakami; Haruhiko Abe; Nobuya Harayama; Yasuhide Nakashima
Journal:  Pacing Clin Electrophysiol       Date:  2003-01       Impact factor: 1.976

6.  Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope : pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators.

Authors:  R Sutton; M Brignole; C Menozzi; A Raviele; P Alboni; P Giani; A Moya
Journal:  Circulation       Date:  2000-07-18       Impact factor: 29.690

7.  Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.

Authors:  M Biffi; G Boriani; P Sabbatani; G Bronzetti; L Frabetti; R Zannoli; A Branzi; B Magnani
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

8.  Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test.

Authors:  R Sheldon; S Rose; P Flanagan; M L Koshman; S Killam
Journal:  Am J Cardiol       Date:  1996-09-01       Impact factor: 2.778

9.  Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension.

Authors:  B P Grubb; D Samoil; D Kosinski; D Wolfe; M Lorton; E Madu
Journal:  Am J Med       Date:  1994-10       Impact factor: 4.965

Review 10.  Idiopathic ventricular tachycardia and fibrillation.

Authors:  B Belhassen; S Viskin
Journal:  J Cardiovasc Electrophysiol       Date:  1993-06
View more
  4 in total

1.  Application Of The American College Of Emergency Physicians (ACEP) Recommendations And a Risk Stratification Score (OESIL) For Patients With Syncope Admitted From The Emergency Department.

Authors:  Adrian Baranchuk; William McIntyre; William Harper; Carlos A Morillo
Journal:  Indian Pacing Electrophysiol J       Date:  2011-10-02

2.  To tilt or not to tilt: what is the question?

Authors:  Carlos A Morillo; Rejane Dillenburg; Juan C Guzmán
Journal:  Clin Auton Res       Date:  2004-12       Impact factor: 4.435

3.  2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry.

Authors:  Jonathan S Steinberg; Niraj Varma; Iwona Cygankiewicz; Peter Aziz; Paweł Balsam; Adrian Baranchuk; Daniel J Cantillon; Polychronis Dilaveris; Sergio J Dubner; Nabil El-Sherif; Jaroslaw Krol; Malgorzata Kurpesa; Maria Teresa La Rovere; Suave S Lobodzinski; Emanuela T Locati; Suneet Mittal; Brian Olshansky; Ewa Piotrowicz; Leslie Saxon; Peter H Stone; Larisa Tereshchenko; Mintu P Turakhia; Gioia Turitto; Neil J Wimmer; Richard L Verrier; Wojciech Zareba; Ryszard Piotrowicz
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05       Impact factor: 1.468

4.  Characterization of a thromboembolic photochemical model of repeated stroke in mice.

Authors:  J Diego Lozano; Denise P Abulafia; Gary H Danton; Brant D Watson; W Dalton Dietrich
Journal:  J Neurosci Methods       Date:  2007-02-01       Impact factor: 2.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.